amifostine anhydrous has been researched along with Benign Cerebellar Neoplasms in 5 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We evaluated the pharmacokinetics of amifostine and WR1065 in pediatric patients with newly diagnosed medulloblastoma to assess the influence of patient covariates, including demographics, clinical characteristics, and genetic polymorphisms, on amifostine and WR1065 pharmacokinetic parameters." | 1.36 | Clinical pharmacokinetics of amifostine and WR1065 in pediatric patients with medulloblastoma. ( Bai, F; Fouladi, M; Gajjar, A; McKibbin, T; Okcu, MF; Panetta, JC; Stewart, CF, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gurney, JG | 1 |
| Bass, JK | 1 |
| Onar-Thomas, A | 1 |
| Huang, J | 1 |
| Chintagumpala, M | 3 |
| Bouffet, E | 1 |
| Hassall, T | 2 |
| Gururangan, S | 2 |
| Heath, JA | 1 |
| Kellie, S | 2 |
| Cohn, R | 1 |
| Fisher, MJ | 1 |
| Panandiker, AP | 1 |
| Merchant, TE | 2 |
| Srinivasan, A | 1 |
| Wetmore, C | 1 |
| Qaddoumi, I | 1 |
| Stewart, CF | 3 |
| Armstrong, GT | 1 |
| Broniscer, A | 2 |
| Gajjar, A | 3 |
| Fouladi, M | 2 |
| Ashley, D | 1 |
| Gronewold, L | 1 |
| Wallace, D | 1 |
| Hale, GA | 1 |
| Kasow, KA | 1 |
| Morris, B | 1 |
| Krasin, M | 1 |
| Kun, LE | 1 |
| Boyett, JM | 1 |
| McKibbin, T | 1 |
| Panetta, JC | 1 |
| Bai, F | 1 |
| Okcu, MF | 2 |
| Paulino, AC | 1 |
| Lobo, M | 1 |
| Teh, BS | 1 |
| South, M | 1 |
| Butler, EB | 1 |
| Su, J | 1 |
| Borsi, JD | 1 |
| Csaki, C | 1 |
| Ferencz, T | 1 |
| Oster, W | 1 |
2 trials available for amifostine anhydrous and Benign Cerebellar Neoplasms
| Article | Year |
|---|---|
Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma.
Topics: Adolescent; Amifostine; Antineoplastic Agents; Cerebellar Neoplasms; Child; Child, Preschool; Cispla | 2014 |
Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma.
Topics: Adolescent; Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cerebellar Neoplasms; | 2008 |
3 other studies available for amifostine anhydrous and Benign Cerebellar Neoplasms
| Article | Year |
|---|---|
Clinical pharmacokinetics of amifostine and WR1065 in pediatric patients with medulloblastoma.
Topics: Adolescent; Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cerebellar Neoplasms; | 2010 |
Ototoxicity after intensity-modulated radiation therapy and cisplatin-based chemotherapy in children with medulloblastoma.
Topics: Adolescent; Amifostine; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cerebe | 2010 |
Administration of Ethyol (amifostine) to a child with medulloblastoma to ameliorate hematological toxicity of high dose carboplatin.
Topics: Amifostine; Antineoplastic Agents; Carboplatin; Cerebellar Neoplasms; Child; Humans; Male; Medullobl | 1996 |